Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 153

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 153
---
 highly compensated officers
on an individual basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing
such disclosure, at the latest, in the annual proxy statement for our first annual meeting of shareholders following the closing of this
offering, which will be filed under cover of a report on Form 6-K.

As
of December 31, 2024, options to purchase 15,000 Ordinary Shares granted to one of our directors were outstanding under our Option Plan
at an exercise price of $9.933 per share. The following table sets forth information regarding options granted to our executive officers
and directors during the year ended December 31, 2024:

| Name                |     | Grant Date     |     | Stock   
 Options |        |     | Exercise 
 Price    |       |     | Expiration     
 Date           |
|:--------------------|:----|:---------------|:----|:--------|-------:|:----|:---------|------:|:----|:---------------|
| Mr. Keith Valentine |     | September 2015 |     |         | 15,000 |     | $        | 9.933 |     | September 2025 |

As
approved by our board of directors, subject to and following the completion of this offering, we intend to grant options to purchase up
to 16,071 Ordinary Shares and up to 194,098 Ordinary Shares to Mr. Pini Ben Elazar and Dr. Ehud Geller, respectively. The options will
have an exercise price of NIS 0.01 and will expire on the ten-year-anniversary of the grant date.

In
addition, the Company will pay a one-time cash bonus of $250,000 to Mr. Ehud Geller upon the completion of this offering.

Engagement Agreements with Executive Officers

We
have entered into written engagement or consultancy agreements with each of our executive officers, including our Chairman, Dr. Ehud Geller
and our Chief Executive officer, Dr. Eli Hazum. These agreements are terminable by either party upon 60 days’ prior written notice.
All of these agreements contain customary provisions regarding noncompetition, confidentiality of information and assignment of inventions.
None of such agreements contain any terms providing for severance benefits. However, the enforceability of the noncompetition provisions
may be limited under applicable law. In addition, we intend to enter into indemnification agreements, subject to the